COVA
- Early Access Program (EAP) authorization in Brazil in February 2022
- Early termination of patient enrolment in April 2022
- Very promising results in November 2022
- Positive final results in February 2023
- Launch of Early Access programs in France and Brazil
- Application for conditional marketing authorisation in Europe and Emergency Use Authorisation (EUA) in the US